Modulador de Interacção Proteína-Proteína
Foram encontrados 63 produtos de "Modulador de Interacção Proteína-Proteína"
17-Allylaminogeldanamycin
CAS:17-AAG is the first clinically tested hsp90 inhibitor that exhibits antitumor activity. Its antitumor effects are documented in vivo for various animal models, including erbB2-dependent breast cancer, prostate cancer models, and melanoma.
Fórmula:C31H43N3O8Pureza:Min. 95%Cor e Forma:PowderPeso molecular:585.69 g/molEED 226 monohydrate
CAS:Potent and selective inhibitor of polycomb repressive complex 2 (PRC2), by binding to the K27me3-pocket of the regulatory EED subunit. Inhibits H3K27 methylation in histone 3. Has anti-tumor activity in murine xenograft models. Synergistic with EZH2 inhibitor against cancer cell growth.
Fórmula:C17H15N5O3S·H2OPureza:Min. 95%Cor e Forma:White To Yellow SolidPeso molecular:387.41 g/molBardoxolone methyl
CAS:Activater of the Nrf2 pathway and an inhibitor of the NF-κB pathway. Possible applications have extended to anti-viral treatment of COVID-19.Fórmula:C32H43NO4Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:505.69 g/molCBR 470-1
CAS:Activates NRF2 signallingFórmula:C14H20ClNO4S2Pureza:Min. 95%Cor e Forma:PowderPeso molecular:365.9 g/molCCG 63808
CAS:Reversible inhibitor of RGS proteins
Fórmula:C25H15FN4O2SPureza:Min. 95%Peso molecular:454.08998AMG 510
CAS:KRAS G12C inhibitor
Fórmula:C30H30F2N6O3Pureza:(%) Min. 98%Cor e Forma:PowderPeso molecular:560.59 g/molAPTO 253
CAS:Induces Kruppel like factor 4 (KLF4) and reduces the expression of MYC. Anti-tumor activity of APTO 253 has been demonstrated in AML and haematological malignancies. Inducing KLP4 expression in ovarian cancer cells using APT0 253 sensitises cells to cisplatin and paclitaxel. BRCA1/2-deficient cancer cells are hypersensitive to APTO 253, which mediates its action by causing DNA damage.
Fórmula:C22H14FN5Pureza:Min. 95%Cor e Forma:SolidPeso molecular:367.38 g/molMCC 950 sodium
CAS:Inhibitor of NLRP3 inflammasome and suppressor of the inflammatory cytokine IL-1β secretion. The compound was tested in diabetic mice and was shown to decrease the incidence of cardiac arrythmias, which are common secondary complications in diabetes mellitus. MCC 950 has potential to reverse diabetes-induced pathologies in cardiac electrophysiology.Fórmula:C20H23N2O5S·NaPureza:Min. 98 Area-%Cor e Forma:White PowderPeso molecular:426.46 g/molVinorelbine
CAS:Produto ControladoMicrotubule disrupter; anti-mitotic drug; anti-cancer alkaloid
Fórmula:C45H54N4O8Pureza:Min. 95%Cor e Forma:SolidPeso molecular:778.93 g/molPaquinimod
CAS:A calcium-binding protein S100A9 inhibitor with immunomodulatory activity that reduces pathology in experimental collagenase-induced osteoarthritis.Fórmula:C21H22N2O3Pureza:Min. 98 Area-%Cor e Forma:White Off-White PowderPeso molecular:350.41 g/molObatoclax mesylate
CAS:Obatoclax mesylate is a synthetic small molecule, which is derived from chemical synthesis with a primary mode of action as a pan-BCL-2 inhibitor. This compound antagonizes multiple anti-apoptotic proteins within the BCL-2 family, ultimately promoting apoptosis in malignant cells. Its ability to inhibit these proteins disrupts the survival mechanisms that cancer cells exploit, potentially restoring apoptotic pathways that are often dysregulated in cancerous tissues.
Fórmula:C20H19N3O·CH4O3SPureza:Min. 95%Cor e Forma:Black SolidPeso molecular:413.49 g/molWS 383 hydrochloride
CAS:Potent inhibitor of the interaction between defective cullin neddylation protein DCN1 and NEDD8-conjugating enzyme UBC12 with IC50 of 11 nM. WS 383 blocks the DCN1-UBC12 interaction in a reversible manner, selectively inhibits Cul3/1 neddylation and induces accumulation of p21, p27, and NRF2 proteins.
Fórmula:C18H20ClN9S2·HClPureza:Min. 95%Cor e Forma:SolidPeso molecular:498.46 g/molSR 18292
CAS:Inhibitor of transcriptional coactivator PGC-1a; anti-diabetic agentFórmula:C23H30N2O2Pureza:Min. 95%Cor e Forma:PowderPeso molecular:366.5 g/mol(2R-)Arimoclomol
CAS:A co-inducer of HSP that acts through heat shock factor 1 (HSF1) in cells undergoing cellular stress. Has therapeutic potential in motor neuron degenerative diseases. Potential treatment for liposomal storage disorders, such as Niemann-Pick disease type C.Fórmula:C14H20ClN3O3Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:313.78 g/molABT 737
CAS:Inhibits anti-apoptotic proteins Bcl-2, Bcl-xl and Bcl-w. Synergistic with chemotherapy and radiotherapy in several tumour cell lines. Potent activity as a single agent in lymphoid cancer and small cell lung cancer (SCLC) cell lines. Causes tumour regression in SCLC xenograft tumour in vivo.
Fórmula:C42H45ClN6O5S2Pureza:Min. 95%Cor e Forma:Yellow SolidPeso molecular:813.43 g/molRCM 1
CAS:Inhibitor of the Forkhead box M1 (FOXM1), an oncogene and a transcription factor regulating cell cycle progression, DNA damage repair and cell renewal. RCM 1 weakens the FOXM1 activity by inhibiting its nuclear localisation and increasing its degradation in proteasomes. The compound showed potential for asthma treatment since it inhibited goblet cell metaplasia and IL-13 signalling in mice.Fórmula:C20H12N2OS4Pureza:Min. 95%Cor e Forma:SolidPeso molecular:424.59 g/molRVX 208
CAS:Inhibitor of BET bromodomainFórmula:C20H22N2O5Pureza:Min. 95%Cor e Forma:PowderPeso molecular:370.4 g/molSirt-IN-1
CAS:Inhibitor of pan-sirtuins (IC50 = 15, 10, 33 µM for SIRT1, 2 and 3 respectively), by binding to the active catalytic site. Selectivity for sirtuins was demonstrated when tested for activity on a panel of kinases, nuclear receptors, ion channels, transporters and GPCRs.Fórmula:C19H27N5O2SPureza:Min. 95%Peso molecular:389.52 g/molNutlin 3A
CAS:Antagonist of proto-oncogene MDM2 and its interaction with p53
Fórmula:C30H30Cl2N4O4Pureza:Min. 95%Peso molecular:581.49 g/molVinorelbine tartrate
CAS:Produto ControladoMicrotubule disrupter; anti-mitotic drug; anti-cancer alkaloidFórmula:C53H66N4O20Pureza:(Hplc) Min. 98.0%Cor e Forma:White PowderPeso molecular:1,079.11 g/mol
